TNFAIP6 and inflammatory bowel disease: It has been demonstrated that tumor necrosis factor stimulated gene 6 (TSG6) is the major effector contributing to the therapeutic effects of MSCs in treating IBD with strong immune suppression capabilities [1, 11, 48–51].